Novel Drug Delivery Systems (NDDS) Market

Novel Drug Delivery Systems (NDDS) Market Outlook

Worldwide demand for novel drug delivery systems (NDDS) is predicted to surge at a CAGR of 6.6% from 2022 to 2027. At present, the global novel drug delivery systems market enjoys a valuation of US$ 62.5 billion and is anticipated to climb to a market size of US$ 86 billion by the end of 2027.

Oral drug delivery systems are projected to be extremely popular over the coming years owing to their ease of administration and the increasing patient-centric approach of the healthcare sector.

Report Attributes	Details
Novel Drug Delivery Systems Market Size (2022)	US$ 62.5 Billion
Projected Year Value (2027F)	US$ 86 Billion
Global Market Growth Rate (2022-2027)	6.6% CAGR
Key Companies Profiled	AstraZeneca PLC Boston Scientific Genzyme Co. Bayer AG Novartis AG Pfizer Inc. Sanofi SA Tolmar GlaxoSmithKline PLC Johnson & Johnson Astellas Aspen Lupin Breckenridge Pharmaceuticals Shire Galen 3M Company Merck & Co. Inc. Teva Pharmaceuticals Industries Limited Abbott Laboratories

Demand Analysis of Novel Drug Delivery Systems (2017-2021) in Comparison to Market Growth Forecasts (2022-2027)

Drug delivery plays a crucial role in the treatment of any disease and hence has been a crucial aspect of the overall healthcare infrastructure. Conventional drug delivery systems are being replaced with advanced and modern drug delivery systems owing to their better efficacy and accuracy. This is expected to drive the novel drug delivery systems market at a CAGR of 6.6% over the next five years.

Increasing prevalence of chronic illnesses, rapid advancements in drug delivery technology, rising investments in the healthcare industry, favorable reimbursement policies, increasing R&D activities, the growing popularity of minimally invasive procedures, and advancements in drug formulation are expected to be prime factors that head the novel drug delivery systems market growth throughout the forecast period.

However, strict regulatory mandates are expected to have a constraining effect on the overall novel drug delivery systems market growth over the years to come. High costs of advanced healthcare procedures and lack of awareness of novel systems for drug delivery are other factors that could potentially restrain NDDS market growth to some extent over the next five years.

Which Prospects are Shaping NDDS Market Growth Path?

“Increasing Use of Drug Delivery Technology to Treat Chronic Diseases”

Drug delivery has been a crucial aspect of treatment for many diseases and with advancements in drug delivery, it has become more important in the treatment of most health conditions. The prevalence of chronic diseases such as cancer has increased exponentially over the past few years and this has led to high demand for novel systems for the delivery of drugs for the treatment procedures.

Drug delivery technology has offered some breakthrough treatment approaches for chronic diseases such as cancer and increasing research and development activities are expected to further advance the use of drug delivery in the treatment of other chronic illnesses.

“Stringent Regulatory Laws May Dwarf NDDS Market Potential”

Drug delivery systems need to undergo a crucial process of approval from regulatory bodies to be launched and used in the market. The presence of strict norms in the process of approval creates a challenge and hinders the overall novel drug delivery systems market potential. This factor is expected to maintain its restraining effect on the industry over the next five years.

Which Regional Market Leads Novel Drug Delivery System Demand?

“North America to Majorly Drives Novel Drug Delivery System Sales”

North America novel drug delivery systems market currently accounts for a major market share and is anticipated to maintain a similar stance throughout the forecast period.

Rising healthcare expenditure, supportive government initiatives, and the presence of key drug delivery system providers are the prime factors that are expected to drive NDDS market growth in this region through 2027.

Increasing investments in the healthcare industry and the emergence of new molecular diagnostic companies in Europe are expected to be major factors that positively influence novel drug delivery system demand.

Rising incidence of chronic illnesses is also expected to favor NDDS market growth through 2027. Germany, Italy, Spain, France, and the United Kingdom are projected to be prime markets for novel drug delivery systems companies in this region.

The novel drug delivery systems market in the Asia Pacific region is expected to provide highly lucrative opportunities in the coming years. Increasing focus on healthcare, rising investments in R&D activities, growing demand for minimally invasive procedures, and increasing availability of modern drug delivery systems are anticipated to be key prospects that drive novel drug delivery systems market potential in this region.

China and India are anticipated to be the prime markets in this region owing to supportive government initiatives and rising investments in the healthcare research and development sector. Japan is also expected to be a noteworthy market in the APAC region over the next five years.

Analysts at Fact.MR, a market research and competitive intelligence provider, have created a comprehensive novel drug delivery systems market research report that lists all the crucial insights of the industry on a regional and segmental basis.

Country-wise Insights

How Can Manufacturers Earn Profits from the U.S. Market?

“Supportive Government Initiatives to Boost R&D Activities & High Healthcare Expenditure”

The market for novel drug delivery systems in the United States is expected to be primarily driven by increasing research and development activities in the country. Increasing investments in the R&D sector by the government and rising healthcare expenditure in the U.S. are also expected to favor novel drug delivery systems market potential through 2027.

Increasing availability of various drug delivery systems and the high prevalence of chronic diseases such as cancer are also anticipated to bolster novel drug delivery systems market growth in the country throughout the forecast period.

Category-wise Insights

Which Mode of Drug Delivery Will Be Popular Going Forward?

“Controlled Drug Delivery Systems to Maintain Dominant Market Stance”

The global novel drug delivery systems market based on mode is bifurcated into controlled drug delivery systems, targeted drug delivery systems, and modulated drug delivery systems.

Controlled drug delivery systems are anticipated to be widely preferred across the world over the coming years. The ability to offer controlled drug release from these delivery systems helps maximize the efficacy of the drug and is also pivotal in controlling drug toxicity. Improved patient outcomes are also expected to boost demand for controlled drug delivery systems across the forecast period.

Meanwhile, the demand for targeted drug delivery systems is projected to rise at the fastest CAGR through 2027. The increasing use of targeted drug delivery systems in cancer treatment is expected to drive their demand over the years to come.

Which Route of Administration is Popular in NDDS?

“Oral Drug Delivery Systems to Lead NDDS Market Potential”

The global novel drug delivery systems market, based on route, is segmented into oral drug delivery systems, injectable drug delivery systems, pulmonary drug delivery systems, transdermal drug delivery systems, and others.

High patient compliance is a major factor that drives the popularity of oral drug delivery systems across the world. Other factors that benefit the demand for oral drug delivery systems are ease of production and formulation, ease of administration, hassle-free storage, etc. This segment provides lucrative opportunities in the novel drug delivery systems marketplace over the coming years.

Novel ocular drug delivery systems and novel ophthalmic drug delivery systems are anticipated to witness a rise in popularity throughout the forecast period as advancements in the drug delivery industry pick up the pace.

Competitive Landscape

Key companies in the novel drug delivery systems market are expected to bolster their focus on the launch of new and modern drug delivery systems equipped with advanced technologies.

• In June 2022, Gulfic Biosciences Ltd., an innovative pharmaceutical company, announced the launch of a new drug delivery system. The new drug delivery system technology was developed by Gulfic and its French counterpart at an affordable price. The new system is called Dual Chamber Bags (DCB).
• In May 2022, Jabil Healthcare, a leading name in the healthcare industry, announced the launch of a reusable drug delivery device with a broader spectrum of applications. The Qfinity Autoinjector Platform will be available at lower costs than its market alternatives and is expected to further bolster the sustainability trend in the drug delivery industry owing to its reusable nature.

NDDS market players are also expected to eye acquisitions, partnerships, and mergers to enhance their business scope and expand their market presence across the world.

• Bayer, a German biotechnology and pharmaceutical organization, in August 2021, announced the acquisition of Vividion Therapeutics to strengthen its portfolio of novel drug discovery platforms. The acquisition was valued at US$ 1.5 billion.
• In June 2022, Accord Biopharma and EVERSANA partnered to launch the CAMCEVI (leuprolide) 42mg injection emulsion that is expected to be used for the treatment of prostate cancer in adults.

Key Segments of NDDS Industry Research

• By Route :

  • Oral Drug Delivery Systems
  • Injectable Drug Delivery Systems
  • Pulmonary Drug Delivery Systems
  • Transdermal Drug Delivery Systems
  • Others

• By Mode :

  • Targeted Drug Delivery Systems
  • Controlled Drug Delivery Systems
  • Modulated Drug Delivery Systems

• By Region :

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • MEA